Back to the list
Congress: ECR25
Poster Number: C-27870
Type: Poster: EPOS Radiologist (scientific)
Authorblock: A. Iozzelli, A. Cipriani, L. Costarelli; Macerata/IT
Disclosures:
Andrea Iozzelli: Nothing to disclose
Antonio Cipriani: Nothing to disclose
Leonardo Costarelli: Nothing to disclose
Keywords: Breast, Contrast agents, Oncology, MR, Biopsy, Cancer
Purpose This work aims to investigate the safety, characteristics, and diagnostic efficacy of the novel paramagnetic contrast agent gadopiclenol, recently available in Europe, in patients undergoing magnetic resonance imaging (MRI) for the detection and characterization of breast abnormalities.
Read more Methods and materials We selected 18 consecutive women (mean age 46 ± 10yrs.) who performed a high-field MRI scan (1,5T, Sola, Siemens – Erlangen, Germany) at our institution for the detection and characterization of breast abnormalities. These patients were previously investigated with standard full-field digital mammography (FFDM) projections, including digital breast tomosynthesis (DBT) and ultrasound (US) imaging. 50% of the patients were also submitted to US-guided core biopsy using a 14G tru-cut needle.Patients were placed inside the magnet in the prone position, with...
Read more Results In all cases, a strong enhancement of both breast lesions, if present, and vascular map of breast veins was observed (Fig.7). The maximum percentage enhancement was varying quite widely from 45 to 387% (mean=217±119%), including benign and malignant foci.In 17 patients (95%), no adverse reaction or local/general discomfort related to the contrast agent administration was detected. In one patient, a cutaneous rash on the chest was observed 30 minutes after MRI, considered of uncertain origin. The patient was successfully treated...
Read more Conclusion In our small cohort of consecutive patients, breast MRI with the intravenous administration of gadopiclenol showed a strong enhancement of lesions and veins in all cases, proving to be clinically safe and providing images of optimum quality for the detection and characterization of breast abnormalities. Further studies, including a wider cohort of patients and comparison with other gadolinium-based contrast agents, should be conducted to obtain more robust results.
Read more References Bashir MR, Thomas KL. A New Generation of Gadolinium-based MRI Contrast Agents: Higher Relaxivity, Lower Dose. Radiology. 2023 Jul;308(1):e231454. doi: 10.1148/radiol.231454. Kuhl C, Csőszi T, Piskorski W, Miszalski T, Lee JM, Otto PM. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology. 2023 Jul;308(1):e222612. doi: 10.1148/radiol.222612. Robert P, Vives V, Grindel AL, et al. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model. Radiology....
Read more
GALLERY